-
AN OPEN-ARCHITECTURE PLATFORM FOR SEASONAL INFLUENZA TRANSMISSION MODELING AND HEALTH ECONOMIC EVALUATION
Aug 11, 2026, 17:16 PM -
ASSESSING ACCURACY, CLINICAL UTILITY, AND FAIRNESS OF RISK STRATIFICATION ALGORITHMS FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) EXACERBATIONS
Aug 11, 2026, 17:16 PM -
PSYCHOMETRIC VALIDATION OF THE EQ-5D-5L BREATHING BOLT-ON IN A US-BASED LONGITUDINAL COHORT WITH ASTHMA AND COPD
Aug 11, 2026, 17:16 PM -
TWENTY YEARS OF HEALTH TECHNOLOGY ASSESSMENT IN IRELAND- TRENDS IN ECONOMIC EVALUATION, PRICE NEGOTIATION, AND REIMBURSEMENT TIMELINES (2006-2025)
Aug 11, 2026, 17:16 PM -
HEALTH-RELATED QUALITY OF LIFE OUTCOMES IN PSYCHEDELIC-ASSISTED THERAPY TRIALS FOR PTSD: A RAPID REVIEW
Aug 11, 2026, 17:16 PM -
PREVALENCE OF DISORDERS OF GUT-BRAIN INTERACTION (DGBIS) AND THE IMPACT OF COMORBID FOOD HYPERSENSITIVITY ON HEALTHCARE-SEEKING BEHAVIOUR: A CROSS-SECTIONAL ANALYSIS
Aug 11, 2026, 17:16 PM -
IS A CURATIVE GENE THERAPY FOR MULTIPLE SCLEROSIS COMMERCIALLY VIABLE? A RISK-ADJUSTED NET PRESENT VALUE ANALYSIS
Aug 11, 2026, 17:16 PM -
HAVE NICE'S INCREASED COST-EFFECTIVENESS THRESHOLDS IMPROVED TECHNOLOGY APPRAISAL OUTCOMES?
Aug 11, 2026, 17:16 PM -
TRENDS IN 12-MONTH MORTALITY AND STATUTORY HEALTH INSURANCE COSTS IN INCIDENT METASTATIC BLADDER CANCER IN GERMANY, 2011-2024
Aug 11, 2026, 17:16 PM -
A FEASIBILITY ASSESSMENT OF AN ANCHORED INDIRECT TREATMENT COMPARISON BETWEEN ENEBOPARATIDE (CALYPSO) AND PALOPEGTERIPARATIDE (PATHWAY) IN CHRONIC HYPOPARATHYROIDISM
Aug 11, 2026, 17:16 PM -
SOCIO DEMOGRAPHIC, CLINICAL CHARACTERISTICS AND TREATMENTS OF ALZHEIMER'S DISEASE PATIENTS WITH PSYCHOTIC SYMPTOMS _ MEMORA COHORT
Aug 11, 2026, 17:16 PM -
DEVELOPMENT AND VALIDATION OF A DECISION-ANALYTIC MODEL USING REAL-WORLD DATA FOR EARLY HEALTH TECHNOLOGY ASSESSMENT OF CARDIOVASCULAR DISEASE RISK SCREENING WITH A POLYGENIC RISK SCORE
Aug 11, 2026, 17:16 PM -
DOES UNMET NEED SHAPE THE INDIRECT COMPARATIVE EVIDENCE SUBMITTED FOR HTA? EVIDENCE FROM PRECISION ONCOLOGY ACROSS SEVEN COUNTRIES
Aug 11, 2026, 17:16 PM -
EVOLUTION OF THE PROFILE AND DURATION OF ONCOLOGICAL TREATMENT IN LUNG CANCER IN THE ONCOLOGY PHARMACY UNIT
Aug 11, 2026, 17:16 PM -
REDUCING HALLUCINATIONS IN HEOR APPLICATIONS THROUGH RETRIEVAL OPTIMIZATION AND CONTEXT ENGINEERING TECHNIQUES
Aug 11, 2026, 17:16 PM -
FIRST INSIGHTS FROM GERMAN HEALTH DATA LAB: REAL-WORLD EPIDEMIOLOGY AND OUTCOMES OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) IN GERMANY
Aug 11, 2026, 17:16 PM -
ECONOMIC BURDEN OF TUBERCULOSIS FOR PATIENTS AND HOUSEHOLDS IN SUB-SAHARAN AFRICA: A SYSTEMATIC REVIEW OF COST-OF-ILLNESS STUDIES
Aug 11, 2026, 17:16 PM -
A BUDGET IMPACT ANALYSIS FOR THE INTRODUCTION OF A TUMOUR-INFORMED CTDNA TEST TO GUIDE ADJUVANT CHEMOTHERAPY (ACT) DECISIONS IN PATIENTS WITH STAGE II AND III COLORECTAL CANCER (CRC) IN GREECE
Aug 11, 2026, 17:16 PM -
SOCIOECONOMIC BURDEN AND SOCIETAL VALUE OF INNOVATIVE DMT IN THE TREATMENT OF MULTIPLE SCLEROSIS IN ALGERIA
Aug 11, 2026, 17:16 PM -
WHAT MAKES DIGITAL HEALTH VALUABLE? A MULTIDIMENSIONAL PREFERENCE STUDY FOR HTA AND REIMBURSEMENT DECISIONS
Aug 11, 2026, 17:16 PM
